Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
WVE 
Wave Life Sciences Ltd (WVE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: WVE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -43.34% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.19B USD | Price to earnings Ratio - | 1Y Target Price 23.27 |
Price to earnings Ratio - | 1Y Target Price 23.27 | ||
Volume (30-day avg) 1146343 | Beta -1.04 | 52 Weeks Range 4.25 - 16.74 | Updated Date 04/2/2025 |
52 Weeks Range 4.25 - 16.74 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.7 |
Earnings Date
Report Date 2025-03-04 | When - | Estimate -0.225 | Actual 0.27 |
Profitability
Profit Margin -89.57% | Operating Margin (TTM) 27.42% |
Management Effectiveness
Return on Assets (TTM) -22% | Return on Equity (TTM) -73.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 911307802 | Price to Sales(TTM) 10.97 |
Enterprise Value 911307802 | Price to Sales(TTM) 10.97 | ||
Enterprise Value to Revenue 8.41 | Enterprise Value to EBITDA -10.12 | Shares Outstanding 153486000 | Shares Floating 70239808 |
Shares Outstanding 153486000 | Shares Floating 70239808 | ||
Percent Insiders 16.53 | Percent Institutions 83.49 |
Analyst Ratings
Rating 4.6 | Target Price 22.3 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Wave Life Sciences Ltd
Company Overview
History and Background
Wave Life Sciences Ltd. was founded in 2012. It focuses on developing genetic medicines using stereopure oligonucleotides targeting RNA. The company has evolved from preclinical research to clinical-stage development, focusing on addressing unmet needs in genetic diseases.
Core Business Areas
- RNA Targeting Therapeutics: Development of novel therapeutics targeting RNA for the treatment of genetic diseases.
Leadership and Structure
Wave Life Sciences Ltd is led by a management team with experience in drug development and biotechnology. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- WVE-N531: An investigational stereopure oligonucleotide for Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. No current market share data available. Competitors include Sarepta Therapeutics.
- WVE-003: An investigational stereopure oligonucleotide targeting mutant huntingtin (mHTT) for Huntington's disease. No current market share data available. Competitors include Roche (Tominersen, discontinued) and uniQure.
Market Dynamics
Industry Overview
The genetic medicine industry is rapidly growing, driven by advancements in RNA therapeutics and gene editing technologies. There's increasing focus on precision medicine and personalized treatments for genetic diseases.
Positioning
Wave Life Sciences focuses on stereopure oligonucleotides which offer potential advantages in specificity and efficacy compared to traditional approaches. The company aims to address unmet needs in specific genetic disorders.
Total Addressable Market (TAM)
The total addressable market for genetic medicines is estimated to be in the tens of billions of dollars. Wave Life Sciences is positioned to capture a share of this market with its targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary stereopure oligonucleotide platform
- Targeting genetically defined diseases with high unmet need
- Experienced management team
Weaknesses
- Clinical development risk
- Limited number of approved products
- Reliance on partnerships and funding
Opportunities
- Expanding pipeline with new targets
- Partnerships with larger pharmaceutical companies
- Advancements in RNA therapeutics and delivery technologies
Threats
- Competition from other genetic medicine companies
- Regulatory hurdles and clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- SRPT
- IONS
- CRSP
Competitive Landscape
Wave Life Sciences competes with established players in the genetic medicine space. Its stereopure oligonucleotide platform differentiates it. They have less market share than the competition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and partnerships.
Future Projections: Future projections are dependent on clinical trial outcomes and regulatory approvals. Analyst estimates vary.
Recent Initiatives: Recent initiatives include advancing clinical programs and expanding partnerships.
Summary
Wave Life Sciences is a clinical-stage biotechnology company that pioneers genetic medicines to potentially cure devastating diseases. The company's stereopure oligonucleotide platform distinguishes it from competitors, offering potential advantages in specificity and efficacy. However, Wave Life Sciences faces significant clinical development risk and relies on partnerships and funding. The company needs to mitigate regulatory hurdles, clinical trial risks, and competition from larger companies to ensure a successful future.
Similar Companies
- SRPT
- IONS
- CRSP
- NTLA
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Data may be outdated. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Wave Life Sciences Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Paul B. Bolno M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 287 | Website https://wavelifesciences.com |
Full time employees 287 | Website https://wavelifesciences.com | ||
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.